Monoclonal antibody
Bimagrumab
An investigational monoclonal antibody that increases lean mass and reduces fat mass through activin type II receptor blockade. It is not a peptide.
Evidence confidence
Human
2/5
Some human clinical evidence
1 citation
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation
Claimed uses
- Moderate
- Moderate
Mechanisms
- not-yet-documented
- Activin type IIB ligand trapping
Safety notes
Potential adverse effects include muscle spasms, diarrhoea, acne and liver-enzyme changes. Long-term cardiovascular and metabolic safety require continued evaluation.
Regulation
- Investigational monoclonal antibody; approval status is indication- and jurisdiction-dependent and should be checked before clinical claims.
References
Last reviewed
12 July 2026